* EXONHIT *
1997 - IDF
Paris
www.exonhit.com Discovery, Diagnostics
(also, Discovery, Drugs)
Key words: RNA splicing, Gene profiling technology, Cancer, Alzheimer
Mission: to leverage on alternative RNA splicing, the process by which a single gene can lead to several proteins in the fields of drug discovery, diagnostics and biochips and to sell proprietary gene profiling technology named Datas in order to identify genes whose splice variants produce abnormal proteins which may trigger or contribute to the development of disease
Clients: Pharmaceutical industry (own development up to phase II)
infofi@exonhit.com
Age: 12 year(s)
Identity| TYPE/MANAGEMENT/INVESTORS | FINANCES/STATUS | | Personal venture |
Managing Dir.-CEO: Maurel (Loïc) [M.D., ex-Debiovision, Novartis, Rhône Poulenc Rorer]
Sc.Dir.-CSO: Pando (Matthew) [Ph.D.] and Jaskowiak (John R.) [ex-Hewlett Packard, Agilent, Affymetrix]
Fin.Dir.-CFO: Duchesne de Lamotte (Hervé) [MBA, Ms (MIT), ex-Stanford Research Institute, AT Kearney France, IDM, Cirrus Finance Management]
BusDev: Vickery (William) [MBA, ex-Roche Pharma]
Comm.Dir.: Hoff (Corinne) [ex-Nicox, Aventis, Novartis)]
Financers (Hist.): CDC Innovation, Sofinnova, Oxford Bioscience Partners, AGF P.E., BNP P.E., Dresdner Kleinwort, Danske Bank, LCF Ed. de Rotschild, Sudinnova, Biomérieux (5.8%, end 2007), Public | Turnover (M€) : 5.2 (2007)
Total funding (M€) : 101.1
Last funding (M€) : 15.6
Focus : Genome
Position : Clinical
Company confirm : 29-Sept-2009 |
History | DATE | MILESTONE | TYPE | TIME | | 2010 .04 | Acquisition of oncology-focused RedPath Integrated Pathology (USA) to accelerate growth in molecular diagnostics | ACQ+ | [12 years] |
| 2010 .03 | Licensing-out to Allergan and BMS of EHT/AGN001 (a compound already in long term contract with Allergan), with upfront payment of 4 MUS$ | LICOUT | [12 years] |
| 2009 .12 | Public offering (4th) on Alternext : 15.6 M€ | PBO | [12 years] |
| 2009 .11 | Launch of AclarusDx, first diagnostic test in Alzheimer available as a Research Use Only product for Pharma industry (first step) | MKTG | [12 years] |
| 2009 .09 | Clinical trial (phase IIa) for EHT 0202 in Alzheimer’s disease (completed) | CLIN | [11 years] |
| 2009 .07 | Round-financing : 1.45 M€ through the exercise of warrant with existing investors | RFIN | [11 years] |
| 2009 .03 | Proof-of-concept for SpliceArray platform for cancer diagnostic, evidence by I.G.R. (publication in Lancet Oncology) | R&D | [11 years] |
| 2008 .06 | Nomination : Loïc Maurel, as CEO | ORGN | [10 years] |
| 2008 .04 | Nomination : Philippe Rousseau as interim CEO after founders' resignation | ORGN | [10 years] |
| 2007 .06 | Public offering (3rd) on Alternext : 3.4 M€ | PBO | [9 years] |
| 2006 .11 | 5th round-financing : 13.5 M€, in convertible bonds | RFINE | [9 years] |
| 2006 .04 | Public offering (2nd) on Alternext : 6.5 M€ | PBO | [8 years] |
| 2005 .11 | Listing on Alternext : 7.3 M€ | PBO | [8 years] |
| 2004 .02 | 4th round-financing : 8.3 M€ in convertible bonds | RFIND | [6 years] |
| 2001 .12 | Licensing-out to Biomérieux (diagnostics) | LICOUT | [4 years] |
| 2001 .12 | 3rd round-financing : 30.0 M€, by Dresdner Kleinwort, Danske Bank, LCF E. de Rothschild, Sudinnova, and previous shareholders | RFINC | [4 years] |
| 2001 .11 | Licensing-out to Allergan (drugs) | LICOUT | [4 years] |
| 2001 .01 | Set-up of US subsidiary in Maryland | ORGC | [3 years] |
| 2000 .09 | 2nd round-financing : 14.0 M€, by AGF P.E. and BNP P.E. | RFINB | [2 years] |
| 1998 .06 | 1st round-financing : 3.7 M€, by CDC Innovation, Sofinnova, Oxford Bioscience Partners (also, 0.8 M€, by ANVAR) | RFINA | [0 year] |
| 1997 .11 | Company founded by Bruno Tocqué [ex-Rhône Poulenc Rorer], Laurent Bracco [ex-RPR], Fabien Schweighoffer [ex-RPR] | ORGF | [0 year] | Actualisation / Updating: 19-Mai-2010 |
|
